Allarity Therapeutics, Inc. Marketable Securities, Gain (Loss)
Allarity Therapeutics, Inc. (ALLR) reported Marketable Securities, Gain (Loss) of -$115.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2023-03-13
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2022-12-31 was -$230.00K.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2022-09-30 was $19.00K.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2022-06-30 was $132.00K.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2022-03-31 was -$36.00K.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for fiscal 2022 was -$115.00K.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for fiscal 2021 was -$495.00K, a 169.92% decline from fiscal 2020.
- Allarity Therapeutics, Inc. marketable securities, gain (loss) for fiscal 2020 was $708.00K.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$211.00K derived: sum of 2 quarters · filed 2023-03-13 | -$79.00K derived: sum of 3 quarters · filed 2023-03-13 | -$115.00K 10-K · filed 2023-03-13 |
| 2022-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $151.00K derived: sum of 2 quarters · filed 2022-11-14 | $115.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $96.00K 10-Q · filed 2022-10-07 | ||
| 2022-03-31 | -$36.00K 10-Q · filed 2022-05-27 | |||
| 2021-12-31 | -$495.00K 10-K · filed 2023-03-13 | |||
| 2020-12-31 | $708.00K 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |